Aridis Pharmaceuticals (NASDAQ:ARDS) has been assigned a $25.00 price objective by investment analysts at Maxim Group in a report released on Thursday, TipRanks reports. The firm presently has a “buy” rating on the stock. Maxim Group’s target price points to a potential upside of 159.61% from the stock’s current price.
ARDS has been the topic of a number of other research reports. Northland Securities reaffirmed a “buy” rating and set a $40.00 price target on shares of Aridis Pharmaceuticals in a report on Wednesday, April 17th. Zacks Investment Research raised Aridis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Tuesday, April 2nd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $27.50.
NASDAQ ARDS traded up $0.23 during trading hours on Thursday, reaching $9.63. The company’s stock had a trading volume of 37 shares, compared to its average volume of 1,667. The stock has a market capitalization of $74.45 million and a P/E ratio of -1.37. Aridis Pharmaceuticals has a 52 week low of $7.59 and a 52 week high of $13.85.
Aridis Pharmaceuticals (NASDAQ:ARDS) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.99) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.87) by ($0.12). The business had revenue of $1.02 million for the quarter. Aridis Pharmaceuticals had a negative net margin of 660.78% and a negative return on equity of 1,961.31%. On average, research analysts anticipate that Aridis Pharmaceuticals will post -2.52 earnings per share for the current year.
About Aridis Pharmaceuticals
Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.
Featured Story: How do taxes affect a CDs total return?
Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.